And he will say that patients suffering from obesity face a “post code lottery” when seeking access to specialist care.
Speaking at the British Pharmacological Society’s Winter Meeting in Brighton today, Dr Nick Finer Clinical Director, Wellcome Clinical Research Facility at Addenbrooke's Hospital in Cambridge, will call for anti-obesity drugs to be more widely used.
Dr Finer will say that these drugs are cost-effective interventions and do work if correctly used.
But he will add that in some patients early potential for drug treatment to prevent the later need for surgery is being missed - due to the reluctance of primary care doctors to treat obesity.
In his presentation, entitled ‘Clinical challenges: can current drugs compete with surgery?’, Dr Finer will be discussing the place of drug treatment in the management of obesity.
Dr Finer said: “About one third of people taking the two drugs currently licensed for obesity management, in conjunction with a diet and lifestyle programme, will achieve a 10 per cent weight loss and around half a five per cent loss. Weight loss is well maintained if drug treatment is continued.
“Drug treatment has also been shown to delay or prevent the development of type 2 diabetes, reduce cardiovascular risk factors and improve well-being.
“These results clearly do not match surgery but could be more generally adopted in clinical care.
“Despite NICE (National Institute for Health and Clinical Excellence) guidelines, there is a reluctance of primary care doctors to treat obesity, with or without drugs, and thus the early potential for drug treatment to prevent the later need for surgery in some people is missed.
“There remains a strong antipathy from many doctors, primary care trusts and specialist commissioning groups to invest in obesity management.
“NICE guidelines - and even more seriously previous Health Technology Assessments - remain to be implemented. There is a complete post code lottery for patients to access specialist care.
“Until the QOF (Quality and Outcomes Framework) system remunerates GPs for undertaking weight management there will be little stimulus for adoption of current evidence-based treatment guidelines.”
Dr Finer is just one of the presenters at a special symposium on Obesity at the BPS Winter Meeting, which also includes a presentation on the regulatory challenges for new anti-obesity drugs. For the full programme please see below.
Cholesterol-lowering drugs may fight infectious disease
22.08.2017 | Duke University
Once invincible superbug squashed by 'superteam' of antibiotics
22.08.2017 | University at Buffalo
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
22.08.2017 | Health and Medicine
22.08.2017 | Materials Sciences
22.08.2017 | Life Sciences